- Clone:
- REA1170 | B4B6
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for CD172b (SIRPβ) Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD172b (SIRPβ) (REA1170) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Fluorescence microscopy image of CD172b (SIRPβ) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD172b (SIRPβ)-PE (REA1170, red) and counterstained with DRAQ5 (blue) as DNA stain.
Overlay histogram showing flow cytometric analysis of CD172b knockout cells. Wild type (red) and knockout cells (blue) were stained with CD172b-PE, clone (REA1170). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD172b (SIRPβ). Human peripheral blood cells after erythrocyte lysis were stained with CD172b (SIRPβ) antibodies followed by a suitable counterstain. As a control, CD172b (SIRPβ) antibody staining was omitted and cells were measured in the same channel. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD172b shown as histograms
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD172b (SIRPβ) (REA1170). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA1170 recognizes the human CD172b antigen, a single-pass type I membrane protein also known as signal-regulatory protein beta (SIRPβ). Signal regulatory proteins (SIRPs) are a family of transmembrane receptor-like signaling proteins that are abundantly expressed in hematopoietic cells, including granulocytes, monocytes, dendritic cells, and lymphocytes. In addition, SIRPs are expressed in neuronal cells and certain types of cancer cells. SIRPs can be divided into two subfamilies, CD172a and CD172b, based on the putative structures of their C-terminal intracellular domains which distinguish them as either activating (CD172b) or inhibitory (CD172a) isoforms. CD172b is expressed on peripheral blood monocytes, dendritic cells, and granulocytes.
Additional information: Clone REA1170 displays negligible binding to Fc receptors.
Signal-regulatory protein β-1 (SIRP-β-1), SIRP-BETA-1, CD172 antigen-like family member B
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Liu, Y. et al. (2005) SIRPbeta1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration. J. Biol. Chem. 280 (43): 36132-36140
- Kharitonenkov, A. et al. (1997) A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386 (6621): 181-186
- Dietrich, J. et al. (2000) Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J Immunol 164 (1): 9-12
You have previously chosen International as your location.
What do you want to do?